JosephMichaelGuentherJr.MD
General Surgery • Edgewood, KYBreast, Surgical Oncology (Other than Breast)
Physician
Are you Dr. Guenther?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 72 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
20 Medical Village Dr Ste 254
Edgewood, KY 41017Phone+1 859-344-1600Fax+1 859-344-0091
Summary
- Dr. Joseph Guenther Jr., MD is a general surgeon in Edgewood, Kentucky. He is currently licensed to practice medicine in Kentucky, Ohio, and California. He is affiliated with St. Elizabeth Edgewood, St. Elizabeth Florence, and St. Elizabeth Fort Thomas.
Education & Training
University of Cincinnati Medical Center/College of MedicineResidency, Surgery, 1987 - 1992
University of Michigan Medical SchoolClass of 1987
Certifications & Licensure
CA State Medical License 1992 - Present
OH State Medical License 2001 - 2027
KY State Medical License 2002 - 2025- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2011
- Top MD Consumers Checkbook
- Fellow American College of Surgeons
Clinical Trials
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Start of enrollment: 2017 May 31
Publications & Presentations
PubMed
- 2 citationsPresurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.Seema A Khan, Xinlei Mi, Yanfei Xu, Luis Z Blanco Jr, Azza M Akasha
JAMA Surgery. 2023-12-01 - 6 citationsThe 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.Maki Yamamoto, Brenda Sickle-Santanello, Timothy Beard, Richard Essner, Brian Martin
Current Medical Research and Opinion. 2023-03-01 - 216 citationsKi67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American Co...Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Rodrigo Franco Gonçalves, Souzan Sanati
Journal of Clinical Oncology. 2017-04-01
Press Mentions
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024November 6th, 2024
